Joseph Magagnoli, from the Columbia VA Health Care System in South Carolina, and colleagues performed a retrospective analysis of data from 368 patients hospitalized with confirmed severe acute respiratory syndrome coronavirus 2 infection: 97 treated with HC, 113 with HC+AZ, and 158 with no HC.
The researchers found that the rates of death were 27.8, 22.1, and 11.4 percent, respectively, in the HC, HC+AZ, and no HC groups.
The rates of ventilation were 13.3, 6.9, and 14.1 percent in the HC, HC+AZ, and no HC groups, respectively.
The risk for death from any cause was higher in the HC group (adjusted hazard ratio [aHR], 2.61; 95 percent confidence interval [CI], 1.10 to 6.17; P = 0.03), but not in the HC+AZ group (aHR, 1.14; 95 percent CI, 0.56 to 2.32; P = 0.72) compared with the no HC group.
Compared with the no HC group, the risk for ventilation was similar in the HC group (aHR, 1.43; 95 percent CI, 0.53 to 3.79; P = 0.48) and in the HC+AZ group (aHR, 0.43; 95 percent CI, 0.16 to 1.12; P = 0.09).
End quote
My reading of it is that the key finding is that the combo of HC+AZ reduces death from any cause by 14% but a P value of 0.72 is less than dead certain.
As I related in a previous post, I attempted to buy Chloroquine Phosphate tablets (not Hydroxycholorquine) and was quoted a price of $501 for 30 pills, but cancelled my order when the Costco pharmacist said the wholesale warehouse could give no delivery date. I guess that was good luck and $500 saved.
